Gelonghui, April 10 | Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK) announced that recently, Shandong Zibo Xinda Pharmaceutical Co., Ltd. (hereinafter referred to as “Xinda Pharmaceutical”), a wholly-owned subsidiary of the company, received the “Drug Supplement Application Approval Notice” for cefaclor capsules (hereinafter referred to as “this product”) approved and issued by the State Drug Administration. The product passed the consistent evaluation of the quality and efficacy of generic drugs.
山东新华制药股份(00719.HK)：全资子公司头孢克洛胶囊通过仿制药一致性评价
Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK): Wholly-owned subsidiary cefaclor capsules passed generic drug consistency evaluation
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.